We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+30.91%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.29B
AUM Growth
+$94.4M
(+7.9%)
Cap. Flow
-$78.5M
Cap. Flow
% of AUM
-6.1%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
207
New
56
Increased
31
Reduced
35
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$30.6M |
| 2 |
uniQure
QURE
|
+$18.4M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$16.5M |
| 4 |
Travere Therapeutics
TVTX
|
+$12.9M |
| 5 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$34.8M |
| 2 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$21.8M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$19.5M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$19.3M |
| 5 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$18.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.11% |
| 2 | Miscellaneous | 14.93% |
| 3 | Consumer Staples | 0.85% |
| 4 | Technology | 0.05% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
| $157M | 12.21% |
14,439,444
| – | – |
|
2
Neurocrine Biosciences
NBIX
$15.2B
| $149M | 11.55% |
3,741,267
+176,000
| +5% | +$6.3M |
|
|
3
Travere Therapeutics
TVTX
$5.89B
| $66.7M | 5.19% |
2,784,980
+844,255
| +44% | +$12.9M |
|
|
TSRO
4
DELISTED
TESARO, Inc.
TSRO
| $56.2M | 4.36% |
978,359
+95,000
| +11% | +$4.48M |
|
|
RLYP
5
DELISTED
RELYPSA INC COM
RLYP
| $52.5M | 4.08% |
1,454,142
+215,000
| +17% | +$7.76M |
|
|
6
Iovance Biotherapeutics
IOVA
$4.24B
| $32.9M | 2.55% |
+2,714,549
| New | +$30.6M |
|
7
Xencor
XNCR
$1.77B
| $29.9M | 2.33% |
1,954,785
+27,614
| +1% | +$436K |
|
|
DYAX
8
DELISTED
DYAX CORPORATION
DYAX
| $29.8M | 2.31% |
1,777,000
-75,000
| -4% | -$1.17M |
|
9
Sarepta Therapeutics
SRPT
$2.19B
| $29.3M | 2.28% |
2,204,652
-607,700
| -22% | -$8.1M |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $26.7M | 2.07% |
557,056
+380,493
| +215% | +$16.5M |
|
11
Talphera
TLPH
$61.8M
| $25.4M | 1.97% |
328,703
| – | – |
|
|
12
uniQure
QURE
$2.99B
| $25.2M | 1.96% |
1,039,332
+843,476
| +431% | +$18.4M |
|
|
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $24.2M | 1.88% |
104,640
| – | – |
|
|
ARAV
14
DELISTED
Aravive, Inc. Common Stock
ARAV
| $24.2M | 1.88% |
257,745
+102,550
| +66% | +$12M |
|
15
Zimmer Biomet
ZBH
$18.8B
| $21.2M | 1.65% |
186,217
+27,501
| +17% | +$3.14M |
|
|
CEMP
16
DELISTED
Cempra, Inc.
CEMP
| $19.6M | 1.53% |
572,500
+325,000
| +131% | +$9.77M |
|
|
RCPT
17
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $19.6M | 1.52% |
118,794
-172,600
| -59% | -$21.8M |
|
18
Acadia Pharmaceuticals
ACAD
$4.61B
| $19.6M | 1.52% |
600,240
-493,041
| -45% | -$16.9M |
|
19
ANI Pharmaceuticals
ANIP
$1.66B
| $19.3M | 1.5% |
307,784
-4,716
| -2% | -$287K |
|
|
OTIC
20
DELISTED
Otonomy, Inc.
OTIC
| $17M | 1.32% |
480,387
+26,081
| +6% | +$892K |
|
|
BLUE
21
DELISTED
bluebird bio
BLUE
| $16.3M | 1.27% |
10,422
-6,948
| -40% | -$9.17M |
|
22
Sonida Senior Living
SNDA
$1.91B
| $15.7M | 1.22% |
40,333
+23,666
| +142% | +$8.7M |
|
|
AGN
23
DELISTED
Allergan plc
AGN
| $14.6M | 1.14% |
49,185
+34,097
| +226% | +$9.72M |
|
|
PFNX
24
DELISTED
Pfenex Inc.
PFNX
| $13.8M | 1.07% |
866,423
+461,758
| +114% | +$5.09M |
|
|
PTLA
25
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $13.5M | 1.05% |
355,000
+330,000
| +1,320% | +$11.3M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2015 Portfolio in Review
As of Q1 2015, Perceptive Advisors held 207 positions worth $1.29B, up 7.9% from $1.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Perceptive Advisors withdrew a net $78.5M in Q1 2015, closing 51 positions and reducing 35 holdings. Its most notable exit was PTC Therapeutics, an estimated $34.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in Iovance Biotherapeutics worth $32.9M.
- Perceptive Advisors's largest Q1 2015 buy was Iovance Biotherapeutics: 2,714,549 shares worth $32.9M.
- Perceptive Advisors added most to uniQure in Q1 2015, an estimated $18.4M increase.
- Perceptive Advisors's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $21.8M.
- Perceptive Advisors fully exited PTC Therapeutics in Q1 2015, selling an estimated $34.8M.
- Perceptive Advisors's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2015.
- Perceptive Advisors opened 56 new positions and closed 51 in Q1 2015.
- Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $1.29B.
Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.